公开(公告)号：US20240309078A1

公开(公告)日：2024-09-19

申请号：US18601222

申请日：2024-03-11

Applicant: Prothena Biosciences Limited

Inventor： Robin BARBOUR ,  Svetlana ALEXANDER ,  Mark E. RENZ ,  Shuning GAI ,  Tarlochan S. NIJJAR ,  Philip James DOLAN, III ,  Philip PAYNE

IPC: C07K16/18

CPC classification number: C07K16/18 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92

Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

公开(公告)号：US20210017278A1

公开(公告)日：2021-01-21

申请号：US17040343

申请日：2019-03-22

Applicant: Tarlochan NIJJAR ,  Philip J. DOLAN, III ,  Robin BARBOUR ,  Prothena Biosciences Limited

Inventor： Tarlochan S. NIJJAR ,  Philip J. DOLAN ,  Robin BARBOUR

IPC: C07K16/28

Abstract: Methods for the treatment of AL amyloidosis associated with the deposition of misfolded immunoglobulin light chain proteins and corresponding uses related to an antibody, such as a 2A4 antibody, or a pharmaceutical formulation comprising the antibody.

公开(公告)号：US20230228772A1

公开(公告)日：2023-07-20

申请号：US18160270

申请日：2023-01-26

Applicant: PROTHENA BIOSCIENCES LIMITED

Inventor： Robin BARBOUR ,  Lynn R. ZIESKE ,  Sarah HAMREN

IPC: G01N33/68 ,  C07K16/18 ,  G01N33/50 ,  G01N33/58 ,  G01N33/543

CPC classification number: G01N33/6896 ,  C07K16/18 ,  G01N33/502 ,  G01N33/58 ,  G01N33/54326 ,  G01N33/582 ,  G01N2333/435 ,  G01N2800/2814 ,  C07K2317/565 ,  C07K2317/24

Abstract: The invention provides methods of detecting alpha-synuclein using a capture antibody and a reporter antibody. The capture antibody binds preferentially to full-length alpha-synuclein phosphorylated at residue 129 (PS129 alpha-synuclein) over unphosphorylated full-length alpha-synuclein. The 11A5 antibody is an example of a suitable capture antibody. The reporter antibody binds to an epitope within residues 40-55 of alpha-synuclein. The 23E8 antibody is an example of such an antibody. Because only a small proportion of alpha-synuclein is phosphorylated high sensitivity of detection below picomolar is advantageous.

公开(公告)号：US20220089702A1

公开(公告)日：2022-03-24

申请号：US16500251

申请日：2018-05-02

Applicant: Robin BARBOUR ,  Svetlana ALEXANDER ,  Mark E. RENZ ,  Shuning GAI ,  Tarlochan NIJJAR ,  Philip James DOLAN ,  Philip PAYNE ,  PROTHENA BIOSCIENCES LIMITED

Inventor： Robin BARBOUR ,  Svetlana ALEXANDER ,  Mark RENZ ,  Shuning GAI ,  Tarlochan S. NIJJAR ,  Philip James DOLAN, III ,  Philip PAYNE

IPC: C07K16/18

Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

公开(公告)号：US20210261652A1

公开(公告)日：2021-08-26

申请号：US17181997

申请日：2021-02-22

Applicant: PROTHENA BIOSCIENCES LIMITED

Inventor： Tarlochan S. Nijjar ,  Robin BARBOUR ,  Philip James DOLAN, III ,  Yue LIU ,  Svetlana ALEXANDER ,  Mark E. RENZ

IPC: C07K16/18 ,  C12N15/63

Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

公开(公告)号：US20190330316A1

公开(公告)日：2019-10-31

申请号：US16097445

申请日：2017-05-02

Applicant: PROTHENA BIOSCIENCES LIMITED

Inventor： Robin BARBOUR ,  Philip James DOLAN ,  Yue LIU

IPC: C07K16/18 ,  A61K47/68 ,  A61P25/28 ,  G01N33/68

Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

公开(公告)号：US20190227082A1

公开(公告)日：2019-07-25

申请号：US16315575

申请日：2017-07-06

Applicant: PROTHENA BIOSCIENCES LIMITED

Inventor： Robin BARBOUR ,  Deniz KIRIK ,  Natalie Regina LANDECK

IPC: G01N33/68 ,  G01N33/543

Abstract: The invention provides methods of detecting both total alpha-synuclein and S129 phosphorylated (pS129) alpha-synuclein using a donor complex, a first acceptor complex, and a second acceptor complex. The donor complex comprises an antibody that specifically binds to alpha-synuclein linked to a support and a donor label. The 4B12 antibody is an example of a suitable antibody in the donor complex. The first acceptor complex for detecting pS129 alpha-synuclein comprises an antibody that preferentially binds to pS129 alpha-synuclein linked to a support and a first acceptor label. The 11A5 antibody is an example of a suitable antibody in the first acceptor complex. The second acceptor complex for detecting alpha-synuclein comprises an antibody that binds to alpha-synuclein regardless of S129 phosphorylation. The LB509 antibody is an example of a suitable antibody in the second acceptor complex. Because both total alpha-synuclein and pS129 alpha-synuclein can be detected simultaneously, qualitatively or quantitatively, it is a useful tool to study human alpha-synuclein phosphorylation events in biospecimens.

公开(公告)号：US20210032319A1

公开(公告)日：2021-02-04

申请号：US16933792

申请日：2020-07-20

Applicant: PROTHENA BIOSCIENCES LIMITED

Inventor： Peter SEUBERT ,  Philip James DOLAN, III ,  Yue LIU ,  Robin BARBOUR

IPC: C07K16/18 ,  A61P25/28

Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

公开(公告)号：US20200369755A1

公开(公告)日：2020-11-26

申请号：US16808209

申请日：2020-03-03

Applicant: PROTHENA BIOSCIENCES LIMITED

Inventor： Tarlochan S. Nijjar ,  Robin BARBOUR ,  Philip James DOLAN, III ,  Yue LIU ,  Svetlana ALEXANDER ,  Mark RENZ

IPC: C07K16/18 ,  C12N15/63

Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

公开(公告)号：US20200331992A1

公开(公告)日：2020-10-22

申请号：US16753307

申请日：2018-10-05

Applicant: PROTHENA BIOSCIENCES LIMITED

Inventor： Joshua Reginald SALMANS ,  Svetlana ALEXANDER ,  Robin BARBOUR ,  Jeffrey N. HIGAKI ,  Tarlochan S. NIJJAR

IPC: C07K16/18 ,  A61K31/713

Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, and for monitoring the efficacy of TTR therapies, among other applications.